Site-specific enrichment of highly sialylated N-glycans in an erythropoietin–hybrid Fc fusion protein
European Journal of Pharmaceutics and Biopharmaceutics · 2026
DOI: 10.1016/j.ejpb.2026.115147 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Juhee Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genexine, Inc., Bio Innovation Park, 172 Magokjungang-ro, Gangseo-gu, Seoul 07796, Republic of Korea; Department of Pharmaceutical Regulatory Science…. Hauptthemen laut MEDLINE: Erythropoietin, Polysaccharides, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Ministry of Food and Drug Safety.
Abstract (Originalsprache)
Erythropoietin-hybrid Fc fusion protein (EPO-hyFc), comprising an EPO domain fused to a hybrid IgD-IgG4 Fc, is a next-generation erythropoiesis-stimulating agent with an approximately two-fold longer serum half-life than darbepoetin alfa, a clinically established long-acting EPO formulation. Although sialylation at Asn-38 and Asn-83 is known to modulate serum stability and half-life, the site-specific N-glycosylation of EPO-hyFc has not been characterized. Here, we performed comprehensive N-glycan profiling using LC-MS/MS glycomics combined with nano-LC-MS/MS glycoproteomic analysis of Glu-C-digested peptides. In total, 23 N-glycans (15 sialylated and 8 neutral) were identified. Site-normalized quantification revealed that Asn-24 was mainly occupied by mono- and di-sialylated glycans (64.9%), whereas Asn-38 (76.9%) and Asn-83 (87.7%) were enriched in tri- and tetra-sialylated structures. The Fc site (Asn-261) contained mainly non-sialylated glycans (94.4%). The average number of sialic acids per N-glycan was 2.2, and the sialic acid-capping ratio was 90.9%, indicating extensive terminal sialylation across the EPO sites. These results provide the first site-specific characterization of N-glycosylation in EPO-hyFc and offer structural and quantitative insights for optimizing its stability, pharmacokinetics, and therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genexine, Inc., Bio Innovation Park, 172 Magokjungang-ro, Gangseo-gu, Seoul 07796, Republic of Korea; Department of Pharmaceutical Regulatory Sciences, Graduate School of Chung-Ang University, 84 Heukseok-ro, Dongjak-gu…
- Department of Pharmaceutical Regulatory Sciences, Graduate School of Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Republic of Korea; Department of Global Innovative Drugs, Graduate School of Chung-Ang…
Förderung
- Ministry of Food and Drug Safety
Zitieren
APA
Park, J., Eom, D., Park, C. S., Moon, C., Kim, S., Lee, S., Lee, J., Shin, J., Jo, Y., Lee, M., & Kim, H. H. (2026). Site-specific enrichment of highly sialylated N-glycans in an erythropoietin–hybrid Fc fusion protein. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115147
Vancouver
Park J, Eom D, Park CS, Moon C, Kim S, Lee S, et al. Site-specific enrichment of highly sialylated N-glycans in an erythropoietin–hybrid Fc fusion protein. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115147
BibTeX
@article{Park2026,
author = {Park, Juhee and Eom, Daeun and Park, Chi Soo and Moon, Chulmin and Kim, Siwon and Lee, Seojeong and Lee, Jihyeon and Shin, Jungmi and Jo, Youngho and Lee, Minji and Kim, Ha Hyung},
title = {Site-specific enrichment of highly sialylated N-glycans in an erythropoietin–hybrid Fc fusion protein},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
doi = {10.1016/j.ejpb.2026.115147}
}
EUVIMED